COSCIENS Biopharma Reports Q1 2025 Results and Updates

Aeterna Zentaris Inc. ( (CSCI) ) has released its Q1 earnings. Here is a breakdown of the information Aeterna Zentaris Inc. presented to its investors.

COSCIENS Biopharma Inc. is a life sciences company that develops and commercializes a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products, leveraging proprietary extraction technology from renewable plant resources.

In its first quarter of 2025, COSCIENS Biopharma Inc. reported a net loss, while continuing to advance its strategic initiatives, including the progression of its Avenanthramides tablets into Phase 2 clinical trials and the commercialization of new nutraceutical products.

Key financial metrics for the quarter reveal a net loss of $3.7 million, attributed to increased operating expenses and a decrease in revenue compared to the previous year. The company ended the quarter with $13.8 million in cash and cash equivalents. Strategic developments include the successful completion of Phase 1 trials for Avenanthramides tablets and the launch of Phase 2a clinical trials.

The company is also focusing on expanding its nutraceutical portfolio with products like Oat Beta Glucan Chewable Bar and Yeast Beta Glucan Powder, while leveraging its Pressurized Gas eXpanded Technology for small-scale commercial production.

Looking ahead, COSCIENS Biopharma Inc. remains committed to advancing its clinical trials and expanding its product offerings, with management focused on achieving operational efficiencies and strategic growth in the coming quarters.